CDC Website CDC Website

To Join the NPIN community or

Home » Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)

Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (R01 Clinical Trial Optional)

The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV. This program covers two parallel FOAs of identical scientific scope. This FOA solicits applications for well-developed research projects using the NIH R01 funding mechanism. The companion FOA, RFA-CA-18-014, is a parallel announcement for exploratory/developmental projects using the NIH R21 mechanism.

Funding Organization
Funding Category
Locations
National
Eligible Organizations
Number of Awards Given
4-6 awards.
Award Amount Notes
Application budgets should reflect the actual needs of the proposed project. Application budgets may not exceed $500,000 direct costs per year.
Letter of Intent Date
7/16/18
Application Due Date
8/16/18
Project Start Date
4/1/18
Application Contact
Shane
Woodward
Branch B Chief, Grants Portfolio Management
240-276-6303
woodwars@mail.nih.gov
Technical Contact
Rebecca
L
Huppi, PhD
Program Director
liddellr@exchange.nih.gov
240-781-3324
Fund Duration
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
Subjects
Audiences
Focus Area

Fund Number: 

5382

Fund ID: 

RFA-CA-18-013

Last Updated: 

5/18/18